Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | FPR1 | P21462 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SPR | P35270 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.35 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | PDE1A | P54750 | 1/20 | 0.33 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.33 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25854000 | 0.85 | PDK2 (0.43) | KMT2APDK2PDK1BRD4 | |
| SCHEMBL25562690 | 0.83 | CNR2 (0.39) | CNR2FPR1OPRM1KMT2ASPR | |
| SCHEMBL22366382 | 0.82 | KDM4C (0.42) | CNR2OPRM1KMT2ASPRKDM4C | |
| SCHEMBL22125893 | 0.82 | OPRM1 (0.40) | CNR2OPRM1KMT2ASPRKDM4C | |
| SCHEMBL25530147 | 0.82 | PKM (0.40) | KMT2APDK2PDK1BRD4 | |
| SCHEMBL22319884 | 0.81 | F2 (0.40) | OPRM1KMT2ASPRKDM4CPOLB | |
| SCHEMBL25568579 | 0.77 | PDE4D (0.43) | FPR1PDE4DOPRM1KMT2ASPR | |
| SCHEMBL17454459 | 0.75 | PIK3CD (0.38) | KMT2ABRD4CREBBP | |
| SCHEMBL29629580 | 0.74 | OPRM1 (0.43) | OPRM1KMT2AKDM4CPOLBSRC | |
| SCHEMBL29629564 | 0.74 | KDM4C (0.41) | OPRM1KMT2AKDM4CPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227437-A1 | IMMUNOMODULATOR | HITGEN INC (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20230227437-A1 | IMMUNOMODULATOR | HITGEN INC (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20230159465-A1 | IMMUNOMODULATOR | HITGEN INC. (CN) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159465-A1 | IMMUNOMODULATOR | IL2, IL17A, IL2RA | CNR2 1434/4885FPR1 262/4885PDE4D 2474/4885 |
| US-20230227437-A1 | IMMUNOMODULATOR | IL17A, IL2, IL2RA | CNR2 1393/4885FPR1 437/4885PDE4D 2033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.